Moberg Pharma announces issue of U.S. Patent for Kerasal Nail
STOCKHOLM, March 25, 2015. Moberg Pharma AB (OMX: MOB) today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 8,987,330 for Moberg Pharma’s market-leading product Kerasal Nail ® , an over-the-counter (OTC) product for fungal nails. The patent expires in 2034.
The new U.S. patent comprises composition of matter claims directed to novel formulations for topical application to the nails. Moberg Pharma is pursuing corresponding patent approval in all major territories.
Based on this innovation, Moberg Pharma launched the second generation of its market leading product Kerasal Nail® in the U.S. last year in major drugstores including CVS, Walgreens and Rite-Aid, mass retailers including Walmart and Target and leading grocery chains including Publix and Safeway. Kerasal Nail is the leading product in the U.S OTC fungal nail category with 22% market share in 2014 according to IRI, and available at more than 30,000 outlets. The product is also sold in more than 30 countries worldwide through distributors.
“The new Kerasal Nail patent provides long-term intellectual property protection for our flagship product in the U.S. It also reconfirms our commitment to bringing innovation to underserved niches and our long term goal to be the leading player in nail fungus,” said Peter Wolpert, CEO of Moberg Pharma AB.
About Nail Fungus and Kerasal Nail®
Approximately 10% of the general population suffers from onychomycosis (nail fungus) and a majority of those afflicted go untreated. Kerasal Nail® is a non-prescription product based on a novel formulation of proven compounds and is clinically proven to rapidly improve the appearance of unsightly fungal nails. Kerasal Nail is applied to the damaged nail using a no-mess, silicone tip applicator. Its efficacy and safety have been documented in several clinical trials including more than 600 patients. Kerasal Nail has a unique rapid mechanism of action and has demonstrated compelling treatment results, including visible improvement within 2-4 weeks.
About this information
Moberg Pharma discloses this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 8.30 a.m. (CET) on March 25, 2015.
For additional information contact:
Peter Wolpert, CEO, Telephone: +46 (0)70 - 735 7135, E-mail: email@example.com
Kjell Rensfeldt, VP R&D, Telephone: +46 (0)70 – 712 4532, Email: firstname.lastname@example.org
About Moberg Pharma
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company’s portfolio includes the OTC brands Kerasal®, Jointflex®, Kerasal Nail®, Domeboro®, Vanquish®, and Fergon®. Kerasal Nail® (Emtrix® or Nalox™ in certain ex-U.S. markets) is a leading OTC treatment of nail disorders in the U.S., Canada and several EU markets and is currently being launched in Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focuses on innovative drug delivery of proven compounds and include two phase II assets, MOB-015 (onychomycosis) and BUPI (oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB). For further information, please visit: www.mobergpharma.com .